Spruce Biosciences director gets 1,700 options

Spruce Biosciences director Percival Barretto-Ko received a grant of stock options covering 1,700 shares of Common Stock.

Accepted by SEC EDGAR 05/26/2026 - 04:30 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Spruce Biosciences director Percival Barretto-Ko received a grant of stock options covering 1,700 shares of Common Stock. The options have an exercise price of $52.70 per share and expire on May 20, 2036.

The grant vests on the first anniversary of the grant date and in any case will be fully vested by the company's 2027 annual stockholder meeting, subject to the director's continuous service under the 2020 Equity Incentive Plan. The options also vest in full upon a Change in Control.

Insider Trade Summary

Grant/Award: 1,700 shares

Grant/Award 1 txn

Insider Barretto-Ko Percival

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	1,700	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 1,700 contracts (Direct)

Holdings Before and After: Stock Option (Right to Buy), 0 to 1,700 contracts (Direct)

Footnotes (1)

1. F1. The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

Key Figures

Options granted: 1,700 options Exercise price: $52.70 per share Expiration date: May 20, 2036 +2 more

5 metrics

Options granted 1,700 options Stock Option (Right to Buy) grant to director

Exercise price $52.70 per share Conversion/exercise price of stock options

Expiration date May 20, 2036 Option expiration for 1,700-share grant

Underlying shares 1,700 shares Common Stock underlying the options

Post-grant derivative holdings 1,700 options Total derivative shares following transaction

Key Terms

Stock Option (Right to Buy), Continuous Service, Change in Control, 2020 Equity Incentive Plan

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Continuous Service financial

"subject to the Reporting Person's Continuous Service under the 2020 Equity Incentive Plan"

Change in Control financial

"will vest in full upon a Change in Control as defined in the Plan"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

2020 Equity Incentive Plan financial

"as defined in the 2020 Equity Incentive Plan (the "Plan")"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Spruce Biosciences (SPRB) disclose in this Form 4 filing?

Spruce Biosciences (SPRB) disclosed that director Percival Barretto-Ko received a grant of stock options for 1,700 shares of Common Stock. These options are a compensation award, not an open-market purchase or sale, and follow the company’s 2020 Equity Incentive Plan terms.

How many Spruce Biosciences (SPRB) options were granted to Percival Barretto-Ko?

Percival Barretto-Ko was granted stock options covering 1,700 shares of Spruce Biosciences Common Stock. All 1,700 options were acquired in a single grant and represent his total derivative holdings reported following this transaction in the Form 4 filing.

What is the exercise price and expiration date of the new SPRB stock options?

The granted Spruce Biosciences (SPRB) stock options have an exercise price of $52.70 per share and expire on May 20, 2036. This means the director can buy shares at $52.70 any time before the May 2036 expiration, once the options are vested.

When do Percival Barretto-Ko’s new Spruce Biosciences (SPRB) options vest?

The 1,700 Spruce Biosciences (SPRB) options vest on the first anniversary of the grant date. They will in any case be fully vested by the company’s 2027 annual stockholder meeting, assuming continuous service under the 2020 Equity Incentive Plan through the vesting date.

What happens to the SPRB options if there is a Change in Control?

If a Change in Control occurs, the 1,700 Spruce Biosciences (SPRB) stock options will vest in full. This acceleration is conditioned under the 2020 Equity Incentive Plan and applies regardless of the normal time-based vesting schedule, provided the applicable plan terms are met.

Is this SPRB Form 4 transaction a market buy or sell of shares?

No, this SPRB Form 4 does not report an open-market buy or sell of shares. It records a compensation-related grant of stock options to a director, coded as an acquisition (A), rather than a purchase or sale on the public market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Barretto-Ko Percival

(Last) (First) (Middle)

C/O SPRUCE BIOSCIENCES, INC.

611 GATEWAY BOULEVARD, SUITE 740

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SPRUCE BIOSCIENCES, INC. [ SPRB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$52.7	05/21/2026		A		1,700		(1)	05/20/2036	Common Stock	1,700	$0	1,700	D

Explanation of Responses:

1. The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

	/s/ Samir Gharib, Attorney-in-Fact	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)